5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital

3. Eliem Therapeutics, Inc. (NASDAQ:ELYM)

RA Capital Management’s Stake Value: $236 million

Percentage of RA Capital Management’s 13F Portfolio: 3.27%

Number of Hedge Fund Holders: 8

Eliem Therapeutics, Inc. (NASDAQ:ELYM) is an American company that develops treatments for neurological diseases such as major depressive disorder, seizures, anxiety, and epilepsy. It was founded in 2018 and is headquartered in Redmond, Washington.

Eliem Therapeutics, Inc. (NASDAQ:ELYM) earned -$0.70 in GAAP EPS during its third quarter. The company’s price target was set to $33 by SVB Leernik in a September 2021 analyst note which saw the firm praise Eliem Therapeutics, Inc. (NASDAQ:ELYM)’s chances of clearing regulatory hurdles.

Dr. Kolchinsky’s investment firm held 13 million Eliem Therapeutics, Inc. (NASDAQ:ELYM) shares worth $236 million and  3.27% of its portfolio in Q3.